EP Patent

EP2233566A1 — Generation of pancreatic progenitor cells

Assigned to Opus NV · Expires 2010-09-29 · 16y expired

What this patent protects

The invention relates to in vitro methods for producing pancreatic progenitor cells and cell populations from cells having definitive endoderm germ layer phenotype. The invention further encompasses so-obtained pancreatic progenitor cells and cell populations, compositions comp…

USPTO Abstract

The invention relates to in vitro methods for producing pancreatic progenitor cells and cell populations from cells having definitive endoderm germ layer phenotype. The invention further encompasses so-obtained pancreatic progenitor cells and cell populations, compositions comprising the same, and further uses of said pancreatic progenitor cells and cell populations, such as inter alia for producing functional, insulin-producing beta cells. The invention is of particular relevance for medical applications, more specifically in the field of cell therapy of diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
EP2233566A1
Jurisdiction
EP
Classification
—
Expires
2010-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Opus NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.